Myriad genetics, inc. (MYGN)
Income statement / Yearly
Jun'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10Jun'09
Total revenue

851,100

743,700

769,900

740,500

723,100

778,200

613,200

496,005

402,084

362,648

326,527

Costs and expenses:
Research and development expense

85,900

70,800

74,400

70,600

75,500

67,500

53,700

42,645

27,751

21,873

17,914

Change in the fair value of contingent consideration

1,100

-61,200

-800

-

-

-

-

-

-

-

-

Selling, general, and administrative expense

555,500

435,000

476,400

359,200

366,000

327,100

251,800

208,383

169,841

161,414

138,884

Total costs and expenses

843,500

621,800

721,200

587,100

588,900

503,800

385,200

315,687

244,306

227,573

200,065

Operating income (loss)

7,600

121,900

48,700

153,400

134,200

274,400

228,000

180,318

157,778

135,075

126,462

Other income (expense):
Interest income

3,200

1,800

1,200

900

400

5,400

5,500

4,629

2,226

5,660

12,478

Interest expense

12,000

3,200

6,000

300

-

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

-353

99

-2,493

Other

1,200

-400

-3,000

2,000

300

-2,000

-200

-407

1,873

-

-

Total other income (expense):

-7,600

-1,800

-7,800

2,600

700

3,400

5,300

4,222

-

5,759

9,985

Income (loss) before income tax

0

120,100

40,900

156,000

134,900

277,800

233,300

184,540

159,651

140,834

136,447

Income tax provision (benefit)

-4,400

-13,000

20,600

38,800

54,700

101,600

86,100

72,389

58,941

-11,469

193

Net income (loss)

4,400

133,100

20,300

117,200

-

-

-

-

-

-

-

Net loss attributable to non-controlling interest

-200

-200

-200

-

-

-

-

-

-

-

-

Income from continuing operations

-

-

-

-

-

-

-

-

-

-

136,254

Loss from discontinued operations

-

-

-

-

-

-

-

-

-

-

-51,639

Net income (loss) attributable to Myriad Genetics, Inc. stockholders

4,600

133,300

20,500

117,200

80,200

176,200

147,200

112,151

100,710

152,303

84,615

Earnings (loss) per share:
Continuing operations

-

-

-

-

-

-

-

-

-

-

1.46

Discontinued operations

-

-

-

-

-

-

-

-

-

-

-0.55

Basic

0.06

1.92

0.30

1.67

1.12

2.33

1.82

1.33

1.12

1.58

0.91

Continuing operations

-

-

-

-

-

-

-

-

-

-

1.38

Discontinued operations

-

-

-

-

-

-

-

-

-

-

-0.52

Diluted

0.06

1.85

0.30

1.60

1.08

2.25

1.77

1.30

1.10

1.54

0.86

Weighted average shares outstanding:
Basic

73,500

69,400

68,300

70,000

71,300

75,700

80,900

84,608

89,794

96,338

93,492

Diluted

76,000

72,000

68,800

73,400

74,500

78,200

83,300

86,465

91,704

99,152

98,573

Net income

4,600

133,300

20,500

117,200

80,200

-

-

112,151

100,710

152,303

84,615

Comprehensive income:
Unrealized gain (loss) on available-for-sale securities, net of tax

-

-

-

-

-

-

-

-135

6

-

-

Change in foreign currency translation adjustment, net of tax

-

-

-

-

-

-

-

-178

6

-

-

Comprehensive income

-

-

-

-

-

-

-

111,838

100,722

-

-

Molecular Diagnostic Testing [Member]
Total revenue

789,400

690,400

720,600

692,400

695,500

748,200

582,400

472,390

400,046

362,648

326,527

Total costs and expenses

168,200

148,700

145,200

132,800

132,800

96,100

64,400

51,452

45,637

44,286

43,267

Pharmaceutical and Clinical Services [Member]
Total revenue

61,700

53,300

49,300

48,100

27,600

30,000

30,800

23,615

2,038

-

-

Total costs and expenses

32,800

28,500

26,000

24,500

14,600

13,100

15,300

13,207

1,077

-

-